|D018410||Pneumonia, Bacterial NIH||1.00|
|D008173||Lung Diseases, Obstructive NIH||0.35|
|D008171||Lung Diseases, NIH||0.21|
There is one clinical trial.
The investigators are conducting a national COVID-19 prevalence survey on a sample of 3,000 inhabitants that were randomly selected from the Slovenian population. The sample is representative in age, gender, and geographical distribution. The main objective is to assess how many people in Slovenia have COVID-19 in April/May 2020 and how many were infected with SARS-CoV-2 previously. The investigators are using a direct detection of SARS-CoV-2 RNA in nasopharyngeal samples with validated two-target PCR-based commercial assay. For a serological response to the etiological agent, IgG and IgA anti-SARS-CoV-2 antibodies are measured in plasma samples using a validated commercial assay.
Description: Prevalence of SARS-CoV-2 RNA in nasopharyngeal samplesMeasure: Prevalence of SARS-CoV-2 RNA in nasopharyngeal samples Time: April to May 2020
Description: Prevalence of anti-SARS-CoV-2 antibodies in blood samplesMeasure: Prevalence of anti-SARS-CoV-2 antibodies in blood samples Time: April to November 2020
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports